{"id":1073,"date":"2013-02-01T12:03:00","date_gmt":"2013-02-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/dabigatran-kontraindiziert-bei-mechanischem-herzklappen-ersatz"},"modified":"2013-02-01T12:03:00","modified_gmt":"2013-02-01T11:03:00","slug":"dabigatran-kontraindiziert-bei-mechanischem-herzklappen-ersatz","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/dabigatran-kontraindiziert-bei-mechanischem-herzklappen-ersatz","title":{"rendered":"Dabigatran kontraindiziert bei mechanischem Herzklappen-Ersatz"},"content":{"rendered":"<p>\u00dcber die zugelassenen Indikationen, die zu beachtenden Besonderheiten und \u00fcber Probleme bei Anwendung der neuen oralen Antikoagulanzien (NOA) haben wir mehrfach ausf\u00fchrlich berichtet: Dabigatran (Pradaxa\u00ae; 1), Apixaban (Eliquis\u00ae; 2) und Rivaroxaban (Xarelto\u00ae; 3). Nach Dabigatran und Rivaroxaban ist seit November 2012 auch Apixaban zur Prophylaxe arterieller Thromboembolien bei Patienten mit nicht-valvul\u00e4rem chronischem Vorhofflimmern (VHF) und [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00dcber die zugelassenen Indikationen, die zu beachtenden Besonderheiten und \u00fcber Probleme bei Anwendung der neuen oralen Antikoagulanzien (NOA) haben wir mehrfach ausf\u00fchrlich berichtet: Dabigatran (Pradaxa\u00ae; 1), Apixaban (Eliquis\u00ae; 2) und Rivaroxaban (Xarelto\u00ae; 3). Nach Dabigatran und Rivaroxaban ist seit November 2012 auch Apixaban zur Prophylaxe arterieller Thromboembolien bei Patienten mit nicht-valvul\u00e4rem chronischem Vorhofflimmern (VHF) und [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[137,60,1414,2305,1314,1312,1324,71,519,1004,1003,68,65,256,1328,1327,2685,56,2066,254,253],"class_list":["post-1073","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antikoagulanzien","tag-apoplektischer-insult","tag-blutungen","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-embolie","tag-herzinfarkt","tag-herzklappenerkrankungen","tag-herzklappenersatz","tag-herzklappenfehler","tag-hirninfarkt","tag-myokardinfarkt","tag-nebenwirkungen","tag-neue-orale-antikoagulanzien","tag-noak","tag-re-align-studie","tag-schlaganfall","tag-thromboseprophylaxe","tag-uaw","tag-unerwuenschte-arzneimittelwirkungen"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1073"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1073\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}